Protective Mechanisms of Butyrate on Inflammatory Bowel Disease.
Study Design
- Jenis Studi
- In Vitro
- Populasi
- IBD patients (preclinical/clinical)
- Intervensi
- Protective Mechanisms of Butyrate on Inflammatory Bowel Disease. None
- Pembanding
- None
- Luaran Utama
- Intestinal inflammation modulation
- Arah Efek
- Positive
- Risiko Bias
- Unclear
Abstract
Inflammatory bowel disease (IBD) is a multifactorial chronic disease, commonly associated with alteration in the composition and function of gut microbiota. This process can lead to a decreased production of short chain fatty acids (SCFAs) by the gut microbiota, mainly butyrate, which is an important immunomodulatory molecule in the intestine. Butyrogenic bacteria normally produces butyrate through carbohydrate fermentation or amino acids degradation pathways. This molecule plays an important protective role in intestinal homeostasis acting in both adaptive immunity and innate immunity. This review summarizes the current knowledge about the role of butyrate on the development of IBD and the protective mechanisms of this metabolite on the intestinal mucosa and the whole body, as reported by in vitro and in vivo studies. Thus, butyrate can regulate the activation of regulatory T cells, increasing the acetylation of histones and decreasing the activation of NF-κB. In addition, it can also stimulate the mucus production from epithelial cells and the rearrangement of tight junction proteins.
TL;DR
This review summarizes the current knowledge about the role of butyrate on the development of IBD and the protective mechanisms of this metabolite on the intestinal mucosa and the whole body, as reported by in vitro and in vivo studies.
Used In Evidence Reviews
Similar Papers
Frontiers in immunology · 2019
Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases.
Proceedings of the National Academy of Sciences of the United States of America · 2014
The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition.
Gut · 2014
A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis.
Gut · 2011
Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives.
World journal of gastroenterology · 2018
Relationship between intestinal microbiota and ulcerative colitis: Mechanisms and clinical application of probiotics and fecal microbiota transplantation.
Digestion · 2016